Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097341 | 0.86 | KMT2A (0.49) | KMT2ANR4A2PKMTSHRCYP1A2 | |
| SCHEMBL727030 | 0.84 | CES2 (0.55) | KMT2ANR4A2PKMTSHRCYP1A2 | |
| SCHEMBL22089815 | 0.81 | KMT2A (0.44) | KMT2ATSHRCYP1A2LMNAALDH1A1 | |
| SCHEMBL11632317 | 0.81 | KMT2A (0.50) | KMT2ANR4A2PKMTSHRCYP1A2 | |
| SCHEMBL28037289 | 0.80 | CES2 (0.41) | CYP1A2RAB9ACYP2C19HPGDNPC1 | |
| SCHEMBL246840 | 0.80 | ACHE (0.42) | RAB9AALDH1A1NPC1 | |
| SCHEMBL31149832 | 0.80 | PTPN1 (0.57) | RAB9ANPC1 | |
| SCHEMBL3162903 | 0.80 | PTPN1 (0.57) | RAB9ANPC1 | |
| SCHEMBL2555281 | 0.79 | MAOB (0.40) | RAB9AHDAC6NPC1 | |
| SCHEMBL11739448 | 0.79 | KMT2A (0.58) | KMT2ANR4A2PKMTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | claimed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | claimed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | claimed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | claimed |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| EP-1228060-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032649-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-10 | — | — | WO | disclosed |
| US-4052395-A | AGRICULTURAL FUNGICIDAL COMPOSITIONS CONTAINING 6-(SUBSTITUTED PHENYL)-PYRIDAZINONES AND SAID PYRIDAZINONES | SANKYO COMPANY LIMITED (JA) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | IGF1R, TSHR, TRHR | KMT2A 4480/4885NR4A2 1030/4885PKM 2744/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | KMT2A 4461/4885NR4A2 867/4885PKM 3514/4885 |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | IGF1R, TSHR, TRHR | KMT2A 4480/4885NR4A2 1030/4885PKM 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.